 - Determine the remission rate in patients with NY-ESO-1 or LAGE-1 expressing stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer who are still in complete clinical remission 12 months after initial documentation of remission treated with vaccine therapy comprising vaccinia-NY-ESO-1 vaccine and fowlpox-NY-ESO-1 vaccine. 